Maximum independent set (MIS) is a fundamental problem in graph theory and it has important applications in many areas such as social network analysis, graphical information systems and coding theory. The problem is NP-hard, and there has been numerous studies on its approximate solutions. While successful to a certain degree, the existing methods require memory space at least linear in the size of the input graph. This has become a serious concern in view of the massive volume of today's fast-growing graphs.In this paper, we study the MIS problem under the semi-external setting, which assumes that the main memory can accommodate all vertices of the graph but not all edges. We present a greedy algorithm and a general vertex-swap framework, which swaps vertices to incrementally increase the size of independent sets. Our solutions require only few sequential scans of graphs on the disk file, thus enabling in-memory computation without costly random disk accesses. Experiments on large-scale datasets show that our solutions are able to compute a large independent set for a massive graph with 59 million vertices and 151 million edges using a commodity machine, with a memory cost of 469MB and a time cost of three minutes, while yielding an approximation ratio that is around 99% of the theoretical optimum.
We experimentally demonstrate a quantum key distribution (QKD) protocol using photon pairs entangled in orbit angular momentum (OAM). In our protocol, Alice and Bob modulate their OAM states on each entangled pair with spatial light modulators (SLMs), respectively. Alice uses a fixed phase hologram in her SLM, while Bob designs N different suitable phase holograms and uses them to represent his N -based information in his SLM. With coincidences, Alice can fully retrieve the key stream sent by Bob without information reconciliation or privacy amplification. We report the experiment results with N = 3 and the sector states with OAM eigenmodes | = 1 and | = −1 . Our experiment shows that the coincidence rates are in relatively distinct value regions for the three different key elements. Alice could recover fully Bob's keys by the protocol. Finally, we discuss the security of the protocol both form the light way and against the general attacks.
Chronic itch is one of the most prominent clinical characteristics of diverse systematic diseases. It is a devastating sensation in pathological diseases. Despite its importance, there are no FDA-labelled drugs specifically geared toward chronic itch. The associated complex pathogenesis and diverse causes escalate chronic itch to being one of the top challenges in healthcare. Humanized antibodies against IL-13, IL-4, and IL-31 proved effective in treatment of itch-associated atopic dermatitis but remain to be validated in chronic itch. There are still no satisfactory anti-itch therapeutics available toward itch-related neuropeptides including GRP, BNP, SST, CGRP, and SP. The newly identified potential itch targets including OSM, NMB, glutamate, periostin, and Serpin E1 have opened new avenues for therapeutic development. Proof-of-principle studies have been successfully performed on antagonists against these proteins and their receptors in itch treatment in animal models. Their translational interventions in humans need to be evaluated. It is of great importance to summarize and compare the newly emerging knowledge on chronic itch and its pathways to promote the development of novel anti-itch therapeutics. The goal of this review is to analyze the different physiologies and pathophysiologies of itch mediators, whilst assessing their suitability as new targets and discussing future therapeutic development.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.